Manabu Nakamura joined The Long-Term Credit Bank of Japan, LTCB (currently Shinsei Bank) in 1991, then temporally worked at NED, a venture capital company in LTCB group, since 1994. He was promoted to Managing Director in Shinsei Corporate Investment in 2012. With 19 year experiences in venture investment, He founded Shinsei Capital Partners in 2018. Manabu received BA in economics from Kyoto University and MBA from University of Rochester.
Ryo Fujinami joined Shinsei Corporate Investment in 2016 and then Shinsei Capital Partners in 2019. Prior to Shinsei, he worked for Abbott Japan (previously Dainabot) where he was engaged over 15 years in development of in-vitro diagnostic in oncology, infections, metabolic diseases, and cardiac diseases in its laboratory in Japan. Ryo received BS in engineering from Osaka City University and MS in Science and Engineering from Tokyo Institute of Technology.
Tetsuya Kurihara joined Shinsei Corporate Investment in 2018 and then Shinsei Capital Partners in 2019. Prior to Shinsei, he worked for Investment Banking Division at Citigroup (previously Nikko Citigroup) since 2009, where he was engaged in M&A and financial advisor in Healthcare group. He joined Bayer Yakuhin in 2012 and was in charge of academic-industrial alliances, venture investment, and incubation of biotech / digital health startups in Japan and Germany. Tetsuya graduated from the University of Tokyo.